The Economic Times daily newspaper is available online now.

    Strides Pharma gets USFDA nod for generic ointment to treat skin conditions

    Synopsis

    Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide ointment used for treatment of various skin conditions.

    Medicine reutersReuters
    Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide ointment used for treatment of various skin conditions. The approval is granted to the company's step-down wholly owned subsidiary, Strides Pharma Global, Singapore, by the United States Food and Drug Administration (USFDA) for triamcinolone acetonide ointment USP, 0.05 per cent, Strides Pharma Science said in a regulatory filing.

    "The product is part of the niche and small volume product portfolio with limited competition in the US market," it added. Citing IQVIA data, the company said the US market for triamcinolone acetonide ointment USP, 0.05 per cent, is approximately USD 15 million.

    "The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma in the US market," it added.

    The company has 124 cumulative abbreviated new drug application filings with USFDA of which 86 have been approved and 38 are pending clearance.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    ...more
    The Economic Times

    Stories you might be interested in